As investor interest in early stage life science companies continues to grow, Third Rock has announced the closing of an oversubscribed fund focused on discovering, launching and building innovative life science companies. This is the company's fifth fund and it has raised $2.7 billion since its inception in 2007.
To date, Third Rock has launched or invested in more than 50 companies, which all share a common goal of addressing significant medical needs through bold ideas and transformative science. The firm’s portfolio companies have launched ten products, including five therapeutics, three diagnostics and two devices. Third Rock focuses on building product engine companies, which are built on biological insights and technology platforms, with the potential to generate multiple therapeutics and therefore offer unique opportunity for growth and value creation. With multiple innovative programs in late-stage development across the Third Rock portfolio, there is the potential for these companies to continue to make an impact for patients in need of new and better treatment options.
Third Rock's portfolio includes companies in a large array of life science/medical categories. Some of those categories include: cancer, cardiovascular disease, device, diagnostics, GI, gene therapy, infectious disease.